

Summary of Consolidated Financial Statements for the Nine Months Ended September 30, 2019 (Japanese GAAP)

November 11, 2019

Company name HORIBA, Ltd. Listed stock exchanges: Tokyo Listing code 6856 URL: http://www.horiba.com

Representative Atsushi Horiba, Chairman & Group CEO TEL: (81)75-313-8121

Contact Junichi Tajika, Department Manager, General Administration Division, Accounting Dept.

(Figures have been rounded down to the nearest million yen)

1. Consolidated Results for the Nine Months Ended September 30, 2019 (January 1, 2019 - September 30, 2019)

(1) Consolidated Operating Results (Percentages represent changes from the corresponding period in the previous year) Net Income Attributable **Net Sales** Operating Income Ordinary Income to Owners of Parent Millions of yen Millions of yen Millions of yen Millions of yen Nine months ended 9/30/19 137,030 -6.2 12,005 -32.8 11,557 -34.0 8,426 -37.5 Nine months ended 9/30/18 146,030 17,877 17,518 22.1 13,473 10.4 22.3 24.9

(Note) Comprehensive Income: FY2019Q3 5,319 million yen (-52.5%), FY2018Q3 11,196 million yen (-21.6%)

	Net Income Attributable	Net Income Attributable
	to Owners of Parent	to Owners of Parent
	per Share	per Share (Diluted)
	Yen	Yen
Nine months ended 9/30/19	199.81	198.92
Nine months ended 9/30/18	319.58	318.21

(2) Consolidated Financial Position

	Total Assets	Net Assets	Shareholders' Equity Ratio
	Millions of yen	Millions of yen	%
As of 9/30/19	272,268	161,334	59.0
As of 12/31/18	277,368	162,018	58.2

(Reference) Net assets excluding subscription rights to shares and non-controlling interests:

As of September 30, 2019: 160,571 million yen; As of December 31, 2018: 161,362 million yen

2. Dividends

		Dividend per Share				
	First Second Third quarter quarter quarter		Year end	Total		
	Yen	Yen	Yen	Yen	Yen	
Year ended 12/31/18	_	50.00	_	95.00	145.00	
Year ending 12/31/19	_	50.00	_			
Year ending 12/31/19 (Forecast)				80.00	130.00	

(Note) Changes in the latest dividend forecasts released: None

Total Year-end dividend for fiscal year 2018 of 95 yen per share:

Year-end ordinary dividend of 75 yen and commemorative dividend for the 65th anniversary of the company foundation of 20 yen

3. Consolidated Forecast for the Year Ending December 31, 2019 (January 1, 2019 - December 31, 2019)

(Percentages represent changes from the previous fiscal year)

	Net Sales		Operating Inco	ome	Ordinary Inco	me	Net Income Attrib to Owners of P		Net Income Attributable to Owners of Parent per Share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	207,000	-1.7	23,000	-20.2	22,500	-20.5	16,000	-28.3	379.36

(Note) Changes in the latest business forecasts released: Yes

Notes

(1) Changes in significant subsidiaries during the period

(Changes in specified subsidiaries that caused a change in the scope of consolidation): Yes New one company (company name: HORIBA (China) Co., Ltd.)

- (2) Application of the accounting method specific to quarterly consolidated financial statements: Yes
- (3) Changes in accounting policies, accounting estimates and retrospective restatement
 - ① Changes in accounting policies associated with revision of accounting standards: Yes
 - 2 Changes in accounting policies arising from other than the above: None
 - ③ Changes in accounting estimates: None
 - 4 Retrospective restatement: None
- (4) Number of shares outstanding (common stock)

	September 30,2019	December 31, 2018
① Shares issued (including treasury stock)	42,532,752	42,532,752
② Treasury stock	356,503	362,304
	Jan Sep. 2019	Jan Sep. 2018
3 The average number of outstanding shares	42,174,228	42,159,900

Note 1. This consolidated financial report is not subject to quarterly review by certified public accountants or accounting firms.

Note 2. Appropriate use of business forecasts and other important information

The forecasts of dividend amount and business performance contained in this report have been made based on certain future assumptions, outlooks, and plans which are available at the HORIBA Group as of November 11, 2019. However, due to risks and various uncertain factors such as future business operation policies, changes in the economic environment in Japan and overseas, fluctuation of currency rates, it is possible that actual performance would vary considerably from the forecasts.

1. Qualitative Information Concerning Consolidated Results

(1) Information Concerning Consolidated Operating Results

(For details, see page 10, "3. Supplemental Information - HORIBA, Ltd. Financial Highlights for the Nine Months Ended September 30, 2019")

During the nine months ended September 30, 2019, HORIBA, Ltd. ("the Company") and its consolidated subsidiaries (together "the HORIBA Group" or "HORIBA" as a consolidated group) decreased sales by 6.2% year-on-year to 137,030 million yen, mainly due to a decline in sales in the Semiconductor Instruments & Systems segment. Operating income decreased by 32.8% to 12,005 million yen and ordinary income by 34.0% to 11,557 million yen, and net income attributable to owners of parent by 37.5% to 8,426 million yen.

The operating results of each business segment are summarized as follows.

(Automotive Test Systems)

Sales of emission measurement systems in Asia and Europe increased. As a result, segment sales increased by 7.7% year-on-year to 52,086 million yen. On the profit side, the absence of a temporary expense that occurred in the Americas in 2018 and other factors improved profitability, and contributed to increase operating income by 60.5% to 2,799 million yen.

(Process & Environmental Instruments & Systems)

Due to increase in sales in Japan and Europe, segment sales increased by 2.8% year-on-year to 13,871 million yen. Operating income, however, decreased by 17.5% to 975 million yen, partly due to an increase in R&D expenses.

(Medical-Diagnostic Instruments & Systems)

Segment sales decreased by 2.8% year-on-year to 18,703 million yen, as the depreciation of the euro against the yen deflated sales when translated into yen. On the profit side, operating income decreased by 20.0% to 1,049 million yen, partly due to an increase in R&D expenses.

(Semiconductor Instruments & Systems)

In response to semiconductor manufactures' capital expenditure adjustments, sales to semiconductor production equipment manufactures decreased. Segment sales consequently decreased by 26.1% year-on-year to 33,543 million yen and operating income decreased by 47.1% to 7,437 million yen.

(Scientific Instruments & Systems)

Owning to a decrease in sales mainly in Asia, segment sales decreased by 3.7% year-on-year to 18,824 million yen, while operating loss of 257 million was recorded (compared to operating loss of 414 million yen in the first nine months of the previous year).

(2) Information Concerning Consolidated Earnings Forecasts for FY2019

HORIBA's full year consolidated earnings forecast is as follows:

Consolidated forecast of full year FY2019

(Amount: millions of yen)

	Previous Forecast (As of Aug. 6)	Revised Forecast (As of Nov. 11)	Changes
Net Sales	213,000	207,000	-6,000
Operating Income	25,000	23,000	-2,000
Ordinary Income	24,500	22,500	-2,000
Net Income Attributable to Owners of Parent	17,500	16,000	-1,500

Consolidated forecast of full year FY2019 by segment

Net Sales	(Amount: millions of yen)			
	Previous Forecast (As of Aug. 6)	Revised Forecast (As of Nov. 11)	Changes	
Automotive	85,000	83,000	-2,000	
Process & Environmental	20,000	20,000	-	
Medical	28,000	26,000	-2,000	
Semiconductor	50,000	50,000	1	
Scientific	30,000	28,000	-2,000	
Total	213,000	207,000	-6,000	

Operating Income	(Amount: millions of yen			
	Previous Forecast (As of Aug. 6)	Revised Forecast (As of Nov. 11)	Changes	
Automotive	8,000	7,000	-1,000	
Process & Environmental	2,000	2,000	-	
Medical	2,000	1,500	-500	
Semiconductor	12,000	12,000	-	
Scientific	1,000	500	-500	
Total	25,000	23,000	-2,000	

With regard to consolidated earnings forecasts for the current fiscal year, overall sales forecast has been revised downward by 6,000 million yen to 207,000 million yen, while operating income forecast has been revised downward by 2,000 million yen to 23,000 million yen. This decrease in operating income forecast has led to downward revision by 2,000 million yen in ordinary income forecast and 1,500 million yen in forecast for net income attributable to owners of parent.

By business segment, the Automotive Test Systems segment has revised downward its sales and operating income forecast by 2,000 million yen and 1,000 million yen respectively, after taking into account the recent order trend. In light of the progress achieved up to the third quarter of this year, the Medical-Diagnostic Instruments & Systems segment revised downward its sales and operating income forecast by 2,000 million yen, and the Scientific Instruments & Systems segment revised downward its sales and operating income forecast by 2,000 million yen and 500 million yen and 500 million yen respectively.

(Disclaimer regarding business forecasts)

The forecasts of dividend amount and business performance contained in this report have been made based on certain future assumptions, outlooks, and plans which are available at the HORIBA Group as of November 11, 2019. However, due to risks and various uncertain factors such as future business operation policies, changes in the economic environment in Japan and overseas, fluctuation of currency rates, it is possible that actual performance would vary considerably from the forecasts.

2. Consolidated Financial Statements and Notes

(1) Consolidated Balance Sheets

	Amount: millions of ye		
	FY2018 (As of December 31, 2018)	FY2019 third quarter (As of September 30, 2019)	
ssets			
Current Assets:			
Cash and bank deposits	63,632	63,468	
Trade notes and accounts receivable	59,111	45,560	
Marketable securities	2,399	3,915	
Merchandise and finished goods	20,018	20,784	
Work in process	19,843	23,220	
Raw materials and supplies	15,276	13,837	
Other current assets	8,290	7,916	
Allowance for doubtful accounts	(682)	(65	
Total Current Assets	187,891	178,04	
Fixed Assets:			
Property, Plant and Equipment:			
Buildings and structures, net	37,207	37,72	
Machinery, equipment and vehicles, net	10,244	11,48	
Land	13,692	14,55	
Construction in progress	3,018	3,38	
Other property, plant and equipment, net	4,576	5,06	
Total Property, Plant and Equipment	68,739	72,22	
Intangibles:			
Goodwill	901	1,01	
Software	2,907	2,58	
Other intangibles	1,092	1,72	
Total Intangibles	4,901	5,33	
Investments and Other Non-Current Assets:			
Investment securities	8,359	9,70	
Deferred tax assets	4,636	4,15	
Other investments and other assets	2,917	2,88	
Allowance for doubtful accounts	(76)	(7	
Total Investments and Other Non-Current Assets	15,836	16,66	
Total Fixed Assets	89,477	94,22	
Total Assets	277,368	272,26	

		Amount: millions of ye
	FY2018 (As of December 31, 2018)	FY2019 third quarter (As of September 30, 2019)
Liabilities		
Current Liabilities:		
Trade notes and accounts payable	21,933	18,330
Short-term loans payable	12,044	9,168
Accounts payable - other	15,920	13,165
Accrued income taxes	3,514	1,520
Advances received	17,475	20,583
Accrued bonuses to employees	1,265	2,14
Accrued bonuses to directors and corporate auditors	-	419
Reserve for product warranty	2,012	1,91
Other current liabilities	3,830	4,39
Total Current Liabilities	77,997	71,64
Non-Current Liabilities:		
Corporate bonds	15,000	15,00
Long-term loans payable	17,028	16,89
Deferred tax liabilities	184	14
Net defined benefit liability	1,946	1,83
Provision for loss on dissolution of the employees' pension fund	640	
Other non-current liabilities	2,552	5,41
Total Non-Current Liabilities	37,352	39,28
Total Liabilities	115,349	110,93
Net Assets		
Shareholders' Equity		
Common stock	12,011	12,01
Capital surplus	18,717	18,71
Retained earnings	132,329	134,63
Treasury stock	(1,428)	(1,40
Total Shareholders' Equity	161,630	163,95
Accumulated Other Comprehensive Income		
Net unrealized holding gains on securities	2,788	3,71
Deferred gains or losses on hedges	(2)	(
Foreign currency translation adjustments	(2,829)	(6,90
Remeasurements of defined benefit plans	(224)	(20
Total Accumulated Other Comprehensive Income	(267)	(3,38
Subscription Rights to Shares	549	65
Non-controlling Interests	106	11
Total Net Assets	162,018	161,33
Total Liabilities and Net Assets	277,368	272,268

(2) Consolidated Statements of Income and Consolidated Comprehensive Income Statements (Consolidated Statements of Income)

		Amount: millions of yen
	FY2018 third quarter (Nine months ended	FY2019 third quarter (Nine months ended
	September 30, 2018)	September 30, 2019)
	,	
Net Sales	146,030	137,030
Cost of Sales	83,046	79,691
Gross Income	62,984	57,338
Selling, General and Administrative Expenses	45,107	45,332
Operating Income	17,877	12,005
Non-Operating Income		
Interest income	86	143
Dividend income	104	105
Other	172	371
Total Non-Operating Income	364	447
Non-Operating Expense		
Interest expense	318	333
Foreign exchange losses	319	463
Other	85	98
Total Non-Operating Expense	723	895
Ordinary Income	17,518	11,557
Extraordinary Gain		
Gain on sales of fixed assets	524	111
Reversal of provision for loss on dissolution of the employee's pension fund	-	137
Total Extraordinary Gain	524	249
Extraordinary Loss		
Loss on sales of fixed assets	22	-
Loss on disposal of fixed assets	56	8
Total Extraordinary Loss	79	8
Income before Income Taxes	17,962	11,798
Income taxes (current)	4,928	3,409
Income taxes (deferred)	(458)	(57
Total Income Taxes	4,470	3,351
Net Income	13,491	8,446
Profit attributable to non-controlling interests	18	19
Net Income Attributable to Owners of Parent	13,473	8,426

		j
	FY2018 third quarter (Nine months ended September 30, 2018)	FY2019 third quarter (Nine months ended September 30, 2019)
Net Income	13,491	8,446
Other Comprehensive Income		
Net unrealized holding gains on securities	(745)	930
Deferred gains or losses on hedges	6	1
Foreign currency translation adjustments	(1,571)	(4,082
Remeasurements of defined benefit plans	15	23
Total Other Comprehensive Income	(2,295)	(3,126
Comprehensive Income	11,196	5,319
(Breakdown of comprehensive income)		
Comprehensive income attributable to owners of parent	11,186	5,307
Comprehensive income attributable to non-controlling interests	10	11

(3) Notes to Consolidated Financial Statements

(Significant Change in Scope of Consolidation)

From the third quarter of fiscal 2019, newly-established HORIBA (China) Co., Ltd. has been included in the scope of consolidation.

Application of special accounting for preparing quarterly consolidated financial statement (Calculation method for tax expenses)

The Company and its domestic consolidated subsidiaries calculated income tax expenses by multiplying quarterly income before income taxes by reasonably estimated annual effective tax rate. This tax rate was reasonably estimated after applying the deferred tax accounting to the annual income before income taxes.

Change in accounting policy

(Application of IFRS 16, "Leases" and FASB Accounting Standards Update (ASU) 2016-02, "Leases")

The Company applied IFRS 16, "Leases" and FASB Accounting Standards Update (ASU) 2016-02, "Leases" for foreign subsidiaries from the first quarter of the current fiscal year ending December 31, 2019. The aforementioned standards require a lessee to recognize assets and liabilities generally for all leases on the balance sheet. The impact of this change to the consolidated balance sheet as at September 30, 2019, and the consolidated income statement and statement of comprehensive income for the nine months ended September 30, 2019 is immaterial.

Additional information

(Application of the "Partial Amendments to Accounting Standard for Tax Effect Accounting" (ASBJ Statement No. 28; February 16, 2018), etc.)

As the Company applied "Partial Amendments to Accounting Standard for Tax Effect Accounting" (ASBJ Statement No. 28; February 16, 2018), etc., from the beginning of the first quarter of the current fiscal year, deferred tax assets are presented under investments and other assets and deferred tax liabilities are presented under non-current liabilities.

3. Supplemental Information

HORIBA, Ltd. Financial Highlights for the Nine Months Ended September 30, 2019

	l Results						Amount: mill	ions or yer
	12/2018 Result	12/2019 Result	Changes		12/2018 Result	12/2019 Forecast	Changes	
	3Q (9Months)	3Q (9Months)	Amount	Ratio	Full year	Full year	Amount	Ratio
Net Sales	146,030	137,030	-9,000	-6.2%	210,570	207,000	-3,570	-1.7%
Operating Income	17,877	12,005	-5,871	-32.8%	28,838	23,000	-5,838	-20.2%
Operating Income Ratio	12.2%	8.8%	-3.4P		13.7%	11.1%	-2.6P	
Ordinary Income	17,518	11,557	-5,960	-34.0%	28,316	22,500	-5,816	-20.5%
Ordinary Income Ratio	12.0%	8.4%	-3.6P		13.4%	10.9%	-2.5P	
Net Income Attributable to Owners of Parent	13,473	8,426	-5,046	-37.5%	22,313	16,000	-6,313	-28.3%
Net Income Ratio	9.2%	6.1%	-3.1P		10.6%	7.7%	-2.9P	
US\$	109.60	109.12	-0.48		110.44	110.00	-0.44	
Euro	130.87	122.62	-8.25		130.35	122.00	-8.35	
Net Sales	12/2018 Result	12/2019 Result	Chang	jes	12/2018 Result	12/2019 Forecast	Chang	es
Net Gales	3Q (9Months)	3Q (9Months)	Amount	Ratio	Full year			
Automotive	48,345				ruli yeai	Full year	Amount	Ratio
Process&Environmental		52,086	+3,741	+7.7%	79,656	83,000	+3,343	Ratio +4.2%
1 100033QEIIVIIOIIIIICII(a)	13,499	52,086 13,871	+3,741 +372			-		
Medical	,	•	,	+7.7%	79,656	83,000	+3,343	+4.2%
	13,499	13,871	+372	+7.7% +2.8%	79,656 19,361	83,000 20,000	+3,343 +638	+4.2% +3.3% -0.0%
Medical	13,499 19,240	13,871 18,703	+372	+7.7% +2.8% -2.8%	79,656 19,361 26,012	83,000 20,000 26,000	+3,343 +638 -12	+4.2% +3.3% -0.0% -13.5%
Medical Semiconductor	13,499 19,240 45,401	13,871 18,703 33,543	+372 -537 -11,857	+7.7% +2.8% -2.8% -26.1%	79,656 19,361 26,012 57,785	83,000 20,000 26,000 50,000	+3,343 +638 -12 -7,785	+4.2% +3.3% -0.0% -13.5% +0.9%
Medical Semiconductor Scientific	13,499 19,240 45,401 19,543	13,871 18,703 33,543 18,824	+372 -537 -11,857 -718	+7.7% +2.8% -2.8% -26.1% -3.7%	79,656 19,361 26,012 57,785 27,754	83,000 20,000 26,000 50,000 28,000	+3,343 +638 -12 -7,785 +245	+4.2%
Medical Semiconductor Scientific Total	13,499 19,240 45,401 19,543	13,871 18,703 33,543 18,824	+372 -537 -11,857 -718	+7.7% +2.8% -2.8% -26.1% -3.7% -6.2%	79,656 19,361 26,012 57,785 27,754	83,000 20,000 26,000 50,000 28,000	+3,343 +638 -12 -7,785 +245	+4.2% +3.3% -0.0% -13.5% +0.9% -1.7%
Medical Semiconductor Scientific	13,499 19,240 45,401 19,543 146,030	13,871 18,703 33,543 18,824 137,030	+372 -537 -11,857 -718 -9,000	+7.7% +2.8% -2.8% -26.1% -3.7% -6.2%	79,656 19,361 26,012 57,785 27,754 210,570	83,000 20,000 26,000 50,000 28,000 207,000	+3,343 +638 -12 -7,785 +245 -3,570	+4.2% +3.3% -0.0% -13.5% +0.9% -1.7%
Medical Semiconductor Scientific Total	13,499 19,240 45,401 19,543 146,030	13,871 18,703 33,543 18,824 137,030	+372 -537 -11,857 -718 -9,000	+7.7% +2.8% -2.8% -26.1% -3.7% -6.2%	79,656 19,361 26,012 57,785 27,754 210,570	83,000 20,000 26,000 50,000 28,000 207,000	+3,343 +638 -12 -7,785 +245 -3,570	+4.2% +3.3% -0.0% -13.5% +0.9% -1.7%
Medical Semiconductor Scientific Total Operating Income	13,499 19,240 45,401 19,543 146,030 12/2018 Result 3Q (9Months)	13,871 18,703 33,543 18,824 137,030 12/2019 Result 3Q (9Months)	+372 -537 -11,857 -718 -9,000 Chang	+7.7% +2.8% -2.8% -26.1% -3.7% -6.2%	79,656 19,361 26,012 57,785 27,754 210,570	83,000 20,000 26,000 50,000 28,000 207,000 12/2019 Forecast Full year	+3,343 +638 -12 -7,785 +245 -3,570 Chang	+4.2% +3.3% -0.0% -13.5% +0.9% -1.7% es

-262

-6,614

+156

-5,871

-20.0%

-47.1%

-32.8%

1,823

17,063

28,838

221

1,500

12,000

23,000

500

-323

-5,063

+278

-5,838

-17.8%

-29.7%

+126.2%

-20.2%

1,312

14,052

17,877

(414)

1,049

7,437

12,005

(257)

Medical

Semiconductor

Scientific

Total

3. Consolidated Segment Sales by Destination

Amount: millions of yen

	12/2018 Result	12/2019 Result	Changes		12/2018 Result	12/2019 Forecast	Chang	ges	
	3Q (9Months)	3Q (9Months)	Amount	Ratio	Full year	Full year	Amount	Ratio	
Automotive	48,345	52,086	+3,741	+7.7%	79,656	83,000	+3,343	+4.2%	
Japan	15,687	15,123	-563	-3.6%	23,075	21,000	-2,075	-9.0%	
Asia	11,975	15,152	+3,176	+26.5%	21,672	24,000	+2,327	+10.7%	
Americas	6,646	5,940	-705	-10.6%	11,191	10,500	-691	-6.2%	
Europe	14,036	15,870	+1,833	+13.1%	23,716	27,500	+3,783	+16.0%	
Process&Environmental	13,499	13,871	+372	+2.8%	19,361	20,000	+638	+3.3%	
Japan	6,783	7,366	+583	+8.6%	9,538	10,000	+461	+4.8%	
Asia	3,190	2,806	-383	-12.0%	4,616	4,500	-116	-2.5%	
Americas	1,915	1,816	-99	-5.2%	2,677	3,000	+322	+12.0%	
Europe	1,610	1,882	+272	+16.9%	2,528	2,500	-28	-1.1%	
Medical	19,240	18,703	-537	-2.8%	26,012	26,000	-12	-0.0%	
Japan	4,349	4,701	+351	+8.1%	5,889	6,500	+610	+10.4%	
Asia	4,273	4,107	-166	-3.9%	5,607	5,500	-107	-1.9%	
Americas	3,961	3,867	-93	-2.4%	5,341	5,500	+158	+3.0%	
Europe	6,655	6,026	-629	-9.5%	9,174	8,500	-674	-7.4%	
Semiconductor	45,401	33,543	-11,857	-26.1%	57,785	50,000	-7,785	-13.5%	
Japan	15,484	11,806	-3,678	-23.8%	20,208	18,000	-2,208	-10.9%	
Asia	21,649	14,840	-6,808	-31.4%	26,788	22,000	-4,788	-17.9%	
Americas	5,399	4,400	-999	-18.5%	6,956	6,500	-456	-6.6%	
Europe	2,867	2,496	-371	-13.0%	3,833	3,500	-333	-8.7%	
Scientific	19,543	18,824	-718	-3.7%	27,754	28,000	+245	+0.9%	
Japan	5,173	5,083	-89	-1.7%	7,275	7,500	+224	+3.1%	
Asia	5,165	4,654	-510	-9.9%	7,609	7,000	-609	-8.0%	
Americas	5,189	5,330	+141	+2.7%	7,117	8,000	+882	+12.4%	
Europe	4,015	3,755	-260	-6.5%	5,753	5,500	-253	-4.4%	
Total	146,030	137,030	-9,000	-6.2%	210,570	207,000	-3,570	-1.7%	
Japan	47,478	44,082	-3,395	-7.2%	65,986	63,000	-2,986	-4.5%	
Asia	46,254	41,561	-4,692	-10.1%	66,293	63,000	-3,293	-5.0%	
Americas	23,112	21,355	-1,757	-7.6%	33,283	33,500	+216	+0.6%	
Europe	29,185	30,030	+845	+2.9%	45,006	47,500	+2,493	+5.5%	

4. Capital Expenditures, Depreciation and R&D Expenses

	12/201	8	12/2019			
	3Q (9Months)	Full-year Result	3Q (9Months)	Full-year Forecast		
Capital Expenditures (*)	7,425	10,239	8,373	14,000		
Depreciation	5,277	7,240	6,452	8,000		
R&D Expenses	10,985	15,183	12,284	16,000		

^(*1) Capital Expenditures are investments in tangible and intangible fixed as sets.

^(*2) Amortization of goodwill is included in depreciation.

5. Consolidated Financial Results (Quarterly Comparison)

Amount: millions of yen

2,037

3,722

(167)

4,562

10,994

757

	12/2018 Result			12/2019				
	1Q	2Q	3Q	4Q	1Q Result	2Q Result	3Q Result	4Q Forecast
Net Sales	52,696	47,270	46,063	64,539	45,320	46,287	45,422	69,969
Operating Income	9,199	4,857	3,819	10,961	4,434	3,848	3,722	10,994
Operating Income Ratio	17.5%	10.3%	8.3%	17.0%	9.8%	8.3%	8.2%	15.7%
Ordinary Income	8,968	4,763	3,786	10,798	4,303	3,737	3,517	10,942
Ordinary Income Ratio	17.0%	10.1%	8.2%	16.7%	9.5%	8.1%	7.7%	15.6%
Net Income attributable to Owners of Parent	6,114	4,388	2,970	8,840	2,561	3,209	2,655	7,573
Net Income Ratio	11.6%	9.3%	6.4%	13.7%	5.7%	6.9%	5.8%	10.8%
US\$	108.22	109.12	111.46	112.96	110.22	109.90	107.24	112.64
Euro	133.14	129.96	129.51	128.79	125.16	123.48	119.22	120.14
6. Consolidated Segment	Results (Q	uarterly Co	mparison)				Amount: r	nillions of yen
Net Sales	12/2018 Result			12/2019				
Net Jaies	1Q	2Q	3Q	4Q	1Q Result	2Q Result	3Q Result	4Q Forecast

	IQ	20	30	40	IQ Nesult	ZQ Nesuit	JQ INESUIL	4Q Forecast
Automotive	18,097	14,607	15,640	31,310	16,242	18,138	17,705	30,913
Process&Environmental	4,941	4,306	4,250	5,861	4,791	4,369	4,709	6,128
Medical	6,637	6,497	6,106	6,771	6,307	6,359	6,036	7,296
Semiconductor	16,468	15,875	13,058	12,384	11,548	11,157	10,837	16,456
Scientific	6,551	5,983	7,008	8,210	6,429	6,261	6,132	9,175
Total	52,696	47,270	46,063	64,539	45,320	46,287	45,422	69,969
Operating Income	12/2018 Result			12/2019				
Operating income	1Q	2Q	3Q	4Q	1Q Result	2Q Result	3Q Result	4Q Forecast
Automotive	2,610	(120)	(745)	5,958	905	694	1,199	4,200
Process&Environmental	681	187	314	844	470	193	312	1,024
Medical	552	452	308	511	208	501	339	450

3,812

3,819

131

3,011

10,961

635

2,752

4,434

98

2,647

(188)

3,848

Contact

Investor Relations, Corporate Control Dept, General Administration Division, HORIBA, Ltd.

2, Miyanohigashi-cho, Kisshoin, Minami-ku, Kyoto 601-8510, Japan

5,453

9,199

(97)

4,786

4,857

(448)

E-mail: ir-info@horiba.com

Semiconductor

Scientific

Total